相似文献
1
Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas.
Cytotherapy. 2017 Apr;19(4):445-457. doi: 10.1016/j.jcyt.2017.02.002. Epub 2017 Feb 21.
2
Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL.
Stem Cell Res Ther. 2016 Oct 10;7(1):149. doi: 10.1186/s13287-016-0414-0.
3
A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma.
Mol Pharm. 2011 Oct 3;8(5):1559-72. doi: 10.1021/mp200161f. Epub 2011 Jun 30.
4
Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases.
Oncotarget. 2015 Oct 27;6(33):34774-87. doi: 10.18632/oncotarget.5793.
5
The use of hypoxic cultured mesenchymal stem cell for oncolytic virus therapy.
Cancer Gene Ther. 2013 May;20(5):308-16. doi: 10.1038/cgt.2013.22. Epub 2013 Apr 26.
6
Systemic administration of mesenchymal stem cells loaded with a novel oncolytic adenovirus carrying IL-24/endostatin enhances glioma therapy.
Cancer Lett. 2021 Jul 1;509:26-38. doi: 10.1016/j.canlet.2021.03.027. Epub 2021 Apr 2.
7
A specific subpopulation of mesenchymal stromal cell carriers overrides melanoma resistance to an oncolytic adenovirus.
Stem Cells Dev. 2012 Sep 20;21(14):2689-702. doi: 10.1089/scd.2011.0643. Epub 2012 May 14.
8
Delivery of improved oncolytic adenoviruses by mesenchymal stromal cells for elimination of tumorigenic pancreatic cancer cells.
Oncotarget. 2016 Feb 23;7(8):9046-59. doi: 10.18632/oncotarget.7031.
9
Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model.
Oncotarget. 2017 Jul 11;8(28):45415-45431. doi: 10.18632/oncotarget.17557.
10
Current status and potential challenges of mesenchymal stem cell-based therapy for malignant gliomas.
Stem Cell Res Ther. 2018 Aug 24;9(1):228. doi: 10.1186/s13287-018-0977-z.
引用本文的文献
1
Mesenchymal Stem-Cell-Derived Exosomes as Novel Drug Carriers in Anti-Cancer Treatment: A Myth or Reality?
Cells. 2025 Jan 29;14(3):202. doi: 10.3390/cells14030202.
2
Mesenchymal stem cells - the secret agents of cancer immunotherapy: Promises, challenges, and surprising twists.
Oncotarget. 2024 Nov 22;15:793-805. doi: 10.18632/oncotarget.28672.
3
Adipose-Derived Stem Cells as Carrier of Pro-Apoptotic Oncolytic Myxoma Virus: To Cross the Blood-Brain Barrier and Treat Murine Glioma.
Int J Mol Sci. 2024 Oct 18;25(20):11225. doi: 10.3390/ijms252011225.
4
Endovascular surgical neuro-oncology: advancing a new subspecialty.
J Neurooncol. 2024 Oct;170(1):31-40. doi: 10.1007/s11060-024-04782-4. Epub 2024 Sep 2.
5
Revolutionizing Cancer Treatment: Harnessing the Power of Mesenchymal Stem Cells for Precise Targeted Therapy in the Tumor Microenvironment.
Curr Top Med Chem. 2025;25(3):243-262. doi: 10.2174/0115680266299112240514103048.
6
Development of an optimized, non-stem cell line for intranasal delivery of therapeutic cargo to the central nervous system.
Mol Oncol. 2024 Mar;18(3):528-546. doi: 10.1002/1878-0261.13569. Epub 2023 Dec 26.
7
Oncolytic Adenovirus, a New Treatment Strategy for Prostate Cancer.
Biomedicines. 2022 Dec 15;10(12):3262. doi: 10.3390/biomedicines10123262.
8
Development of Allogeneic Stem Cell-Based Platform for Delivery and Potentiation of Oncolytic Virotherapy.
Cancers (Basel). 2022 Dec 13;14(24):6136. doi: 10.3390/cancers14246136.
9
Enhanced tumor targeting and timely viral release of mesenchymal stem cells/oncolytic virus complex due to GRP78 and inducible E1B55K expressions greatly increase the antitumor effect of systemic treatment.
Mol Ther Oncolytics. 2022 Sep 17;27:26-47. doi: 10.1016/j.omto.2022.09.004. eCollection 2022 Dec 15.
10
Variants of the adeno-associated virus serotype 9 with enhanced penetration of the blood-brain barrier in rodents and primates.
Nat Biomed Eng. 2022 Nov;6(11):1257-1271. doi: 10.1038/s41551-022-00938-7. Epub 2022 Oct 10.
本文引用的文献
1
Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.
Sci Transl Med. 2016 Jun 1;8(341):341ra75. doi: 10.1126/scitranslmed.aad9784.
2
First Approval of Regenerative Medical Products under the PMD Act in Japan.
Cell Stem Cell. 2016 Apr 7;18(4):434-5. doi: 10.1016/j.stem.2016.03.011.
3
Antiangiogenic Therapy for Glioblastoma: Complex Biology and Complicated Results.
J Clin Oncol. 2016 May 10;34(14):1567-9. doi: 10.1200/JCO.2016.66.5364. Epub 2016 Mar 21.
4
Talimogene Laherparepvec: First Global Approval.
Drugs. 2016 Jan;76(1):147-54. doi: 10.1007/s40265-015-0522-7.
5
Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway.
Stem Cells. 2015 Aug;33(8):2400-15. doi: 10.1002/stem.2053. Epub 2015 May 27.
6
Delivery of local therapeutics to the brain: working toward advancing treatment for malignant gliomas.
Ther Deliv. 2015 Mar;6(3):353-69. doi: 10.4155/tde.14.114.
7
Mesenchymal stromal cells for prevention and treatment of graft-versus-host disease: successes and hurdles.
Curr Opin Organ Transplant. 2015 Feb;20(1):72-8. doi: 10.1097/MOT.0000000000000158.
8
Analysis of glioblastoma tumor coverage by oncolytic virus-loaded neural stem cells using MRI-based tracking and histological reconstruction.
Cancer Gene Ther. 2015 Jan;22(1):55-61. doi: 10.1038/cgt.2014.72. Epub 2014 Dec 19.
9
Encapsulated stem cells loaded with hyaluronidase-expressing oncolytic virus for brain tumor therapy.
Mol Ther. 2015 Jan;23(1):108-18. doi: 10.1038/mt.2014.204. Epub 2014 Oct 29.
10
Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy.
J Natl Cancer Inst. 2014 May 16;106(6):dju090. doi: 10.1093/jnci/dju090. Print 2014 Jun.
Zotero 插件